MedTrace Logo

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

NCT05656131 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-03-17

No results posted yet for this study

Summary

This study is planned to include 80 patients with HRD positive HER2-negative advanced breast cancer to receive fluzoparib alone or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with or without camrelizumab in the treatment of HRD positive HER2-negative advanced breast cancer.

Conditions

  • Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Interventions

DRUG

Fluzoparib

Arms A will be treated with fluzoparib alone

DRUG

Fluzoparib+Camrelizumab

Arms B will be treated with fluzoparib in combination with camrelizumab

Sponsors & Collaborators

  • wang shusen

    lead OTHER

Principal Investigators

  • shusen Wang · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-23
Primary Completion
2026-03-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05656131 on ClinicalTrials.gov